Friedreich’s Ataxia Market to Surpass US$ 2,062.9 Mn by 2030

Global Friedreich’s Ataxia Market, by Drug Class (ACE Inhibitors, Beta Blockers, Diuretics, Para-Benzoquinone, and Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$   777.2 million in 2022 and is expected to exhibit a CAGR of 13.0% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Key players operating in market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the global Freidreich’s ataxia market growth over the forecast period.

For instance, in November 2021, Reata Pharmaceuticals, Inc., a U.S.-based pharmaceutical company announced that it received Fast Track Designation from the U.S. Food and Drug Administration (US FDA) for its investigational drug Omaveloxolone indicated for the treatment of Friedreich’s ataxia.

Global Friedreich’s Ataxia Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 519 million cases and 6.3 million deaths due to Coronavirus (COVID-19) were reported up till May 15, 2022, across the globe.

The COVID-19 pandemic has affected several markets across the globe and it is expected to have a similar impact on the global Freidreich’s ataxia market, owing to disruptions in supply of raw materials required for production of drugs and lockdowns. However, the COVID-19 pandemic is expected to have only a limited negative impact post lockdown due to rapid advancements made toward treatments of Friedreich’s ataxia, during the COVID-19 pandemic.

For instance, in September 2021, the Friedrich’s Ataxia (FA) Scientific Symposium was held in the U.S. to showcase advancements made in the field of Friedreich’s ataxia therapeutics. Some of the advances include a Phase 2 clinical trial initiated by PTC Therapeutics, a U.S.-based pharmaceutical company in December 2020, to evaluate its drug candidate Vatiquinone for the treatment of Friedrich’s Ataxia. This clinical trial is expected to be completed by September, 2023.

Browse 49 Market Data Tables and 35 Figures spread through 165 Pages and in-depth TOC on “Friedreich’s Ataxia Market”- Global Forecast to 2030, by Drug Class (ACE Inhibitors, Beta Blockers, Diuretics, Para-Benzoquinone, and Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)), by Route of Administration (Oral, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global Freidreich’s ataxia market, click the link below:

https://www.coherentmarketinsights.com/market-insight/friedreichs-ataxia-market-5034

Key players operating in market are focusing on adoption of inorganic growth strategies such as partnerships, and others, in order to strengthen their position in market. For instance, in May 2020, Chondrial Therapeutics, Inc., a U.S.-based clinical-stage biotechnology company focused on developing treatments for rare disease such as Freidreich’s ataxia, announced the completion of its merger with Zafgen, Inc., a U.S.-based biopharmaceutical company and will now operate as Larimar Therapeutics, Inc.

Key Takeaways of the Global Friedreich’s Ataxia Market:

• Global Freidreich’s ataxia market is expected to exhibit a CAGR of 13.0% over the forecast period, owing to rising research and development activities by market players for development of Freidreich’s ataxia therapeutics. For instance, in November 2020, PTC Therapeutics, Inc. announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults suffering from Friedreich's ataxia (FA).
• Among regions, North America segment is expected to account for the largest market share in 2022, owing to increasing focus of market players on receiving regulatory approvals for advanced treatments for Friedreich’s ataxia in the region. For instance, in February 2021, Retrotope Inc., a U.S.-based pharmaceutical company, announced that it received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (US FDA) for its investigational drug RT001 for the treatment of infantile neuroaxonal dystrophy (INAD) and Friedreich’s ataxia.
• Key players operating in the global Freidreich’s ataxia market include Reata Pharmaceuticals, Inc., Retrotope Inc., Minoryx, PTC Therapeutics, Design Therapeutics, Inc., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Intas Pharmaceuticals Ltd.